Drägerwerk AG & Co. KGaA / Analyst ratings
Price targets
Analyst ratings
3 analysts rated this company in the past 90 days. The average target price is €82.67, this is a change of +27.4% compared to the current price.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 96 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for Drägerwerk at "Buy" with a price target of €96. The medical technology company's order intake has gained momentum, wrote Alexander Galitsa in his review of the latest figures released on Wednesday. Overall, the second-quarter results were good./rob/mf/ag
Publication of the original study: July 16, 2025 / 8:10 a.m. / Time zone not specified in the study
First distribution of the original study: July 16, 2025 / 8:19 a.m. / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Drägerwerk on 'Hold' - Target 67 euros
NEW YORK (dpa-AFX Analyser) - Following preliminary second-quarter figures, analyst Jefferies has maintained its rating for Drägerwerk at "Hold" with a price target of €67. While the medical technology group's order intake was good, sales and margins were weak, Henrik Paganetty wrote in a study released Monday. Overall, he nevertheless called the figures "solid" and also referred to the confirmed annual targets./rob/ck/la
Publication of the original study: July 14, 2025 / 6:25 a.m. / Time zone not specified in the study
First distribution of the original study: July 14, 2025 / 6:25 a.m. / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Drägerwerk's 'Buy' rating - target €85
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its rating for Drägerwerk at "Buy" with a price target of €85. The medical technology group's preliminary half-year figures, presented Friday evening, "exceeded its expectations across the board," wrote Christian Ehmann in his commentary published on Monday./ck/ag
Publication of the original study: July 14, 2025 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Drägerwerk's 'Buy' rating - target €85
HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its rating for Drägerwerk at "Buy" with a price target of €85. The company's medical technology segment is showing temporary weakness, wrote Christian Ehmann in a study published Tuesday. This is primarily due to research and development costs. In the defense business, revenue is expected to triple from 2024 to 2028./bek/ajx
Publication of the original study: June 17, 2025 / 2:00 PM / CEST
First distribution of the original study: June 17, 2025 / Time not specified in the study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for Drägerwerk to 67 euros - 'Hold'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies raised its price target for Drägerwerk from €47 to €67, but maintained its "Hold" rating. Despite strong order intake in the first quarter, weak quarterly sales led to a reduction in its sales forecast in its valuation model, Henrik Paganetty wrote in a study published Wednesday. However, he raised his previously conservative estimates for operating profit (EBIT) – primarily due to the improved product mix. The defense sector could prove to be a growth and margin driver for the company. However, competition remains strong, with better patient monitoring products./tih/edh
Publication of the original study: June 11, 2025 / 9:21 a.m. / ET
First distribution of the original study: June 11, 2025 / 9:21 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 96 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking maintained its rating for Drägerwerk at "Buy" with a price target of €96 following an investor event with the medical and safety technology group's management. His positive assessment of the shares has been substantiated, wrote Alexander Galitsa in his response published on Friday. The long-awaited operational improvements in the safety technology sector appear to be lasting and even create room for improvement in terms of growth and margin improvements. In addition, the business surrounding the networking of medical devices (SDC) has significant long-term potential./mis/ag
Publication of the original study: June 6, 2025 / 8:17 a.m. / CET
First distribution of the original study: June 6, 2025 / 8:17 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 96 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained a "Buy" rating on Drägerwerk with a price target of €96. The medical and safety technology manufacturer's final quarterly figures are in line with the previously published key figures and demonstrate a seasonally subdued start to the year, wrote analyst Alexander Galitsa in a review published Friday. The highlight, however, is the record-high order intake – apart from the coronavirus year of 2020./gl/ajx
Publication of the original study: May 2, 2025 / 8:13 a.m. / CET. First distribution of the original study: May 2, 2025 / 8:22 a.m. / CET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Drägerwerk's 'Buy' rating - target €85
HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its rating for Drägerwerk at "Buy" with a price target of €85 following the company's figures. The medical technology company's preliminary figures demonstrate strong order intake, wrote analyst Christian Ehmann in a study released Tuesday. The outlook for the current year appears promising, but uncertainties remain./mf/mis
Publication of the original study: April 15, 2025 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Drägerwerk on 'Hold' after figures
NEW YORK (dpa-AFX Analyst) - Following preliminary first-quarter figures, analyst Jefferies has maintained its rating for Drägerwerk at "Hold" with a price target of €47. In a quick assessment released on Monday, analyst Henrik Paganetty particularly highlighted the medical technology company's strong order intake. This is the reason why the annual targets were confirmed, he wrote.
Publication of the original study: April 14, 2025 / 2:01 p.m. / ET. First distribution of the original study: April 14, 2025 / 2:01 p.m. / ET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB raises target for Drägerwerk to 96 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has raised its price target for Drägerwerk from €86 to €96 and maintained its "Buy" rating. Despite this year's strong performance, the medical technology provider's shares still appear attractive, wrote analyst Alexander Galitsa in a study released Friday. The burden of the US tariffs is manageable./mf/mis
Publication of the original study: April 4, 2025 / 8:21 a.m. / CET
First distribution of the original study: April 4, 2025 / 8:21 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research raises target for Drägerwerk to 85 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has raised its price target for Drägerwerk from €55 to €85 and maintained its rating at "Buy." According to his reassessment published on Tuesday, analyst Christian Ehmann now believes the medical technology company can achieve higher margins. However, he remains cautious about 2026./ag/tav
Publication of the original study: April 1, 2025 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - Target 86 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for Drägerwerk at "Buy" with a price target of €86. Analyst Alexander Galitsa wrote in his commentary published on Tuesday that, for once, the price rally in Drägerwerk shares should be pursued. The price gains have so far only scratched the surface of the overall valuation opportunities./ag/bek
Publication of the original study: January 21, 2025 / 8:22 a.m. / CET
First distribution of the original study: January 21, 2025 / 8:22 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB raises target for Drägerwerk to 86 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking raised its price target for Drägerwerk from €70 to €86 following preliminary quarterly figures and maintained its "Buy" rating. These figures are encouraging in every respect, concluded analyst Alexander Galitsa in a study published Thursday. With the exception of the pandemic years, both business segments have recorded record-high orders. The medical and safety technology manufacturer's total order intake is 9 percent higher than its forecast./bek/la
Publication of the original study: January 16, 2025 / 8:23 a.m. / CET
First distribution of the original study: January 16, 2025 / 8:25 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Drägerwerk's 'Buy' rating - target 55 euros
HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its rating for Drägerwerk at "Buy" with a price target of €55 following preliminary figures. The medical technology manufacturer exceeded estimates for operating profit (EBIT) and order intake, wrote analyst Christian Ehmann in a quick assessment released Thursday. The orders formed a solid foundation for the current fiscal year./mf/tav
Publication of the original study: January 16, 2025 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in the study / Time not specified in the study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Drägerwerk on 'Hold' - target 47 euros
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for Drägerwerk at "Hold" with a price target of €47. The medical and safety technology manufacturer presented strong figures, analyst Henrik Paganetty wrote on Wednesday following the Lübeck-based company's key figures. The year 2024 was mixed overall. The outlook is in line with market expectations./ajx/zb
Publication of the original study: January 15, 2025 / 4:28 PM / ET First distribution of the original study: January 15, 2025 / 4:28 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 70 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its "Buy" rating for Drägerwerk ahead of earnings, with a price target of €70. The medical technology company's fourth quarter is likely to have been seasonally strong, analyst Alexander Galitsa wrote in a study released Friday. The news regarding new products is favorable in light of recent innovations./mf/mis
Publication of the original study: January 10, 2025 / 8:05 a.m. / CET
First distribution of the original study: January 10, 2025 / 8:09 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB counts Drägerwerk among its 'Top Picks' 2025
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for Drägerwerk at "Buy" with a price target of €70. The stock is one of the bank's favorites for 2025. Investors have apparently largely written off the company's medical technology business, as the share price suggests, wrote analyst Alexander Galitsa in a study published Monday. This is unjustified. Furthermore, the security technology business offers compelling growth prospects. Added to this is the prospect of significantly increased dividends to shareholders./mis/zb
Publication of the original study: January 6, 2025 / 8:55 a.m. / CET
First distribution of the original study: January 6, 2025 / 8:58 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 70 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its "Buy" rating for Drägerwerk with a price target of €70. The potential sale of Uvex underscores the stock's undervaluation, analyst Alexander Galitsa wrote in his commentary published Thursday. Uvex, with its safety products, tends to serve the mass market, while Drägerwerk focuses on markets with higher barriers to entry and less price sensitivity. Galitsa also praised the fact that the path has recently been paved for non-dilutive distributions./ag/gl
Publication of the original study: December 5, 2024 / 8:15 a.m. / CET. First distribution of the original study: December 5, 2024 / 8:15 a.m. / CET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 70 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its "Buy" rating for Drägerwerk with a price target of €70. The final figures for the third quarter would have provided some additional details, wrote analyst Alexander Galitsa in his commentary published on Wednesday. Despite the unpredictable medical turnaround, the risk/reward ratio is highly asymmetric./ag/mis
Publication of the original study: October 30, 2024 / 8:32 a.m. / CET
First distribution of the original study: October 30, 2024 / 8:32 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 70 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for Drägerwerk at "Buy" with a price target of €70. Following the presentation of preliminary quarterly figures and confirmed annual targets, the medical technology company's share price fell seven percent, analyst Alexander Galitsa wrote in a report published Thursday. While sales were weaker than expected, this was largely due to the weak medical business in China, he wrote. This, in turn, is considered temporary and can therefore hardly justify the severe price losses./ck/bek
Publication of the original study: October 17, 2024 / 8:12 a.m. / CEST
First distribution of the original study: October 17, 2024 / 8:13 a.m. / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Drägerwerk's 'Buy' rating - target EUR 64
HAMBURG (dpa-AFX Analyser) - The analyst firm Warburg Research has maintained its rating for Drägerwerk at "Buy" with a price target of €64 following preliminary quarterly figures. The medical technology company's order intake was in line with its forecast, wrote analyst Christian Ehmann in a study released Wednesday. However, revenue and operating profit (EBIT) were weaker than expected./edh/bek
Publication of the original study: October 16, 2024 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Drägerwerk on 'Hold' - target 47 euros
NEW YORK (dpa-AFX Analyst) - Following preliminary third-quarter figures, analyst Jefferies has maintained its rating for Drägerwerk at "Hold" with a price target of €47. The medical and safety technology manufacturer's order intake increased compared to the same period last year, analyst Henrik Paganetty wrote in an initial assessment on Wednesday. Net sales, however, declined slightly year-on-year./bek/mis
Publication of the original study: October 16, 2024 / 2:31 a.m. / ET
First distribution of the original study: October 16, 2024 / 2:31 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Hauck Aufhäuser IB maintains Drägerwerk at 'Buy' - target 70 euros
HAMBURG (dpa-AFX Analyst) - Hauck Aufhäuser Investment Banking has maintained its rating for Drägerwerk at "Buy" with a price target of €70. It is hard to dispute that the shares are undervalued, wrote analyst Alexander Galitsa in his commentary published on Monday. He therefore remains highly convinced of his buy recommendation./ag/gl
Publication of the original study: September 30, 2024 / 8:28 a.m. / CEST First distribution of the original study: September 30, 2024 / 8:28 a.m. / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies upgrades Drägerwerk to 'Hold' - target raised to 47 euros
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has upgraded Drägerwerk from "Underperform" to "Hold" and raised its price target from €42 to €47. Valuations for small and medium-sized European companies remain at low levels – unlike for large caps – according to analyst Martin Comtesse in a study published Tuesday. While a broad-based recovery is still a long way off, interest rates in the eurozone have already begun to reverse the trend. Regarding the medical technology company Drägerwerk, Comtesse emphasizes the significantly improved profitability. The basis for this is an improved pricing policy and strict cost management. In addition, there are initial signs of improvement from China./gl/tih
Publication of the original study: September 2, 2024 / 7:15 PM / ET First distribution of the original study: September 2, 2024 / 7:15 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.